Physician profile
Norma Solis
NPI 1790791622
$5,637.27
in general payments reported to CMS, 2019-2025
36 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $874 · 2021: $1,201 · 2022: $839 · 2023: $409 · 2024: $738 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,592.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $715.07 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $615.38 | 2019-2025 | |
| Lilly USA, LLC | $467.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $391.58 | 2019-2025 | Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $206.04 | 2022-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $202.58 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Jazz Pharmaceuticals INC. | $186.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.04 | 2019-2023 | |
| Sanofi Pasteur INC. | $111.64 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $107.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.04 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $79.40 | 2021 | |
| Abbott Laboratories | $77.44 | 2019-2023 | Freestyle Libre 2 |
| Alexion Pharmaceuticals, INC. | $73.08 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.01 | 2019-2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $51.69 | 2021 | |
| Phathom Pharmaceuticals, INC. | $48.26 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $41.68 | 2021 | |
| Dexcom, INC. | $37.80 | 2023-2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $37.13 | 2019 | |
| Mannkind Corporation | $32.46 | 2019-2021 | |
| Abbvie INC. | $29.39 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.62 | 2024 | Dupixent |
| Allergan, INC. | $23.39 | 2021 | |
| Kyowa Kirin, INC. | $22.44 | 2025 | |
| Seqirus USA INC | $21.72 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Phadia US INC. | $20.32 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.61 | 2023 | Rexulti |
| Exact Sciences Corporation | $17.72 | 2025 | Cologuard Collection Kit |
| Medtronic Vascular, INC. | $17.56 | 2019 | |
| Dynavax Technologies Corporation | $15.69 | 2022 | |
| Genentech USA, INC. | $15.12 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.